Kalyani Charitable Trust's, R.G Sapkal College of Pharmacy, Sapkal Knowledge Hub, Kalyani Hills, Anjaneri, Trimbakeshwar Rd, Nashik, 422213, Maharashtra, India.
Gastroretentive drug delivery systems (GRDDS) have emerged as an advanced approach to overcome the limitations of conventional oral drug delivery, particularly for drugs with a narrow absorption window, poor solubility in intestinal fluids, or instability in alkaline pH. By prolonging gastric residence time, GRDDS enhance drug bioavailability, provide sustained release, and improve therapeutic efficacy. Various mechanisms such as floating, mucoadhesion, swelling, and raft formation have been explored to achieve effective gastric retention. This review provides a comprehensive overview of GRDDS, including gastric physiology, classification of systems, formulation approaches, and evaluation parameters. It also highlights the role of polymers in controlling drug release and discusses recent advances such as 3D printing, nanotechnology-based systems, smart polymers, and artificial intelligence-assisted formulation design. In addition, the review examines the therapeutic applications of GRDDS in the treatment of gastric infections, ulcers, diabetes, and hypertension, along with commercially available formulations demonstrating their clinical relevance. Despite their advantages, GRDDS face challenges related to physiological variability, regulatory requirements, and large-scale manufacturing. Future perspectives emphasize the need for personalized drug delivery systems, improved regulatory frameworks, and integration of innovative technologies to enhance system performance. In conclusion, GRDDS represent a significant advancement in modern pharmaceutics by improving drug delivery efficiency and patient compliance. Continued research and technological innovation are expected to further expand their potential in clinical applications and pharmaceutical development.
Gastroretentive drug delivery systems (GRDDS) are specialized oral controlled-release formulations designed to prolong the residence time of dosage forms in the stomach, thereby enhancing drug bioavailability and therapeutic efficacy. These systems are particularly useful for drugs that exhibit site-specific absorption in the upper gastrointestinal tract or have a narrow absorption window. By maintaining the drug in the gastric region for an extended period, GRDDS can overcome limitations associated with rapid gastric emptying and variable intestinal transit times1.
Conventional oral drug delivery systems, although widely used due to their convenience and patient compliance, are often associated with several challenges. These include unpredictable gastric emptying rates, variable absorption profiles, and reduced bioavailability for drugs that are poorly soluble or unstable in intestinal pH conditions. Additionally, drugs that are absorbed primarily in the upper part of the gastrointestinal tract may exhibit incomplete absorption when administered through traditional dosage forms, leading to suboptimal therapeutic outcomes2. The short residence time of conventional formulations in the stomach further limits the effectiveness of drugs requiring prolonged gastric exposure3.
The concept of gastric retention has therefore gained significant importance in modern pharmaceutics. Prolonging gastric residence time allows for sustained drug release at the desired site of absorption, improves dissolution of poorly soluble drugs in acidic environments, and enhances local therapeutic effects in the stomach. GRDDS can also minimize drug degradation in the intestine and reduce dosing frequency, thereby improving patient compliance. Various approaches such as floating systems, bioadhesive systems, and expandable systems have been developed to achieve effective gastric retention4.
Certain categories of drugs particularly benefit from GRDDS. These include drugs with a narrow absorption window in the upper gastrointestinal tract, such as levodopa, riboflavin, and certain antibiotics. Additionally, drugs that are locally active in the stomach, such as antacids and drugs used in the treatment of Helicobacter pylori infections, are ideal candidates for gastroretentive systems5. Drugs that are unstable or poorly soluble in alkaline pH conditions also show improved performance when formulated as GRDDS6.
The present review aims to provide a comprehensive overview of the advances in gastroretentive drug delivery systems. It focuses on the physiological basis of gastric retention, classification of GRDDS, formulation strategies, evaluation methods, and recent technological developments. Furthermore, the review highlights current challenges and future perspectives, offering insights into the potential of GRDDS in enhancing drug therapy and addressing limitations of conventional oral delivery systems.
1. Physiology of the Stomach Relevant to Gastroretentive Drug Delivery Systems (GRDDS):
A comprehensive understanding of gastric physiology is essential for the rational design of gastroretentive drug delivery systems (GRDDS). Gastric anatomy, pH variability, motility patterns, and physiological factors influencing gastric emptying collectively determine the performance and retention of dosage forms in the stomach. These parameters directly impact drug dissolution, absorption, and overall therapeutic efficacy.
1.1 Gastric Anatomy and pH Variations:
The human stomach is anatomically divided into four major regions: fundus, body, antrum, and pylorus. The fundus and body primarily serve as storage regions, while the antrum plays a crucial role in grinding and mixing gastric contents before emptying into the duodenum7. This functional differentiation is important for GRDDS, as dosage forms designed for buoyancy or adhesion are typically retained in the upper regions of the stomach.
Gastric pH is highly variable and depends on physiological conditions such as fasting and fed states. In the fasting state, gastric pH is typically acidic, ranging from 1.0 to 3.0, whereas in the fed state, it may rise to 3.0–6.0 due to the buffering effect of food. This pH variability significantly influences drug solubility and stability. Drugs that are more soluble in acidic environments benefit from prolonged gastric residence, making GRDDS particularly suitable for such compounds.
Figure 1: Anatomical structure of the human stomach showing fundus, body, antrum, and pylorus relevant to gastroretentive drug delivery systems.
1.2 Gastric Emptying Mechanism:
Gastric emptying is a complex physiological process that regulates the passage of gastric contents into the small intestine. It is influenced by factors such as the physical state of the dosage form (liquid or solid), caloric content of food, and gastric motility patterns8. Liquids generally empty faster than solids, while indigestible solids may remain in the stomach until the occurrence of specific motility cycles.
For GRDDS, controlling gastric emptying is critical, as rapid emptying can lead to premature drug release and reduced bioavailability. Dosage forms designed to float, swell, or adhere to the gastric mucosa can resist gastric emptying and prolong residence time, thereby enhancing drug absorption1.
1.3 Migrating Myoelectric Complex (MMC):
The migrating myoelectric complex (MMC) is a cyclic motility pattern that occurs during the fasting state and plays a key role in gastric emptying. It consists of four distinct phases:
Phase III is particularly significant, as it acts as a “housekeeping wave” that clears indigestible materials from the stomach into the small intestine9. This phase can lead to the expulsion of gastroretentive dosage forms, thereby limiting their effectiveness. Designing GRDDS that can withstand or avoid this phase is a major challenge in formulation development.
1.4 Factors Affecting Gastric Retention:
Several physiological and external factors influence gastric retention time, which in turn affects the performance of GRDDS.
1.4.1 Food Intake:
The presence of food in the stomach significantly prolongs gastric retention time. High-fat and high-calorie meals can delay gastric emptying, thereby enhancing the retention of dosage forms10. In the fed state, the MMC is temporarily suppressed, allowing dosage forms to remain in the stomach for extended periods. This phenomenon is often utilized in GRDDS design to improve drug bioavailability.
1.4.2 Posture:
Body posture can influence gastric motility and the position of dosage forms within the stomach. For example, an upright posture may facilitate faster gastric emptying compared to a supine position11. The orientation of the stomach and gravitational effects can impact the distribution and retention of gastroretentive systems, particularly floating dosage forms.
1.4.3 Disease Conditions:
Various disease states can alter gastric physiology and affect the performance of GRDDS. Conditions such as gastroparesis, diabetes, and peptic ulcers can significantly delay gastric emptying, whereas hyperthyroidism may accelerate it12. Additionally, variations in gastric pH and motility associated with diseases can influence drug stability and release kinetics. Understanding these pathological conditions is essential for optimizing GRDDS for specific patient populations.
2. Need and Advantages of Gastroretentive Drug Delivery Systems (GRDDS):
Gastroretentive drug delivery systems (GRDDS) have emerged as a promising approach to overcome the limitations of conventional oral dosage forms. By prolonging gastric residence time, these systems enhance drug absorption, improve therapeutic outcomes, and provide controlled drug release. GRDDS are particularly beneficial for drugs with site-specific absorption, poor solubility in intestinal fluids, or instability in alkaline environments. The key advantages of GRDDS are discussed below.
2.1 Improved Bioavailability:
One of the primary advantages of GRDDS is the enhancement of drug bioavailability. Many drugs exhibit a narrow absorption window in the upper gastrointestinal tract, particularly in the stomach and proximal small intestine. Conventional dosage forms may pass rapidly through this region, resulting in incomplete absorption and reduced therapeutic efficacy2.
GRDDS prolong the residence time of the drug in the stomach, thereby increasing the duration available for absorption. This is especially beneficial for drugs that are poorly soluble at higher pH levels but dissolve readily in the acidic gastric environment. By maintaining the drug in its optimal absorption site, GRDDS significantly improve bioavailability and reduce variability in plasma drug concentrations1.
2.2 Sustained Drug Release:
GRDDS are designed to provide controlled and sustained release of drugs over an extended period. By retaining the dosage form in the stomach, these systems allow for gradual drug release, maintaining consistent plasma drug levels and minimizing fluctuations associated with conventional immediate-release formulations6.
Sustained release not only enhances therapeutic efficacy but also reduces the risk of dose dumping and adverse effects. Various formulation strategies, such as floating systems and swelling matrices, are employed to achieve prolonged drug release while ensuring gastric retention6.
2.3 Reduced Dosing Frequency:
The ability of GRDDS to provide sustained drug release translates into reduced dosing frequency. Drugs that would otherwise require multiple daily doses can be administered less frequently when formulated as gastroretentive systems13.
This reduction in dosing frequency is particularly advantageous for chronic conditions requiring long-term therapy, as it simplifies treatment regimens and enhances patient adherence. It also minimizes the risk of missed doses and ensures more consistent therapeutic outcomes.
2.4 Targeted Drug Delivery in the Stomach:
GRDDS enable site-specific drug delivery in the stomach, making them particularly useful for drugs intended to exert a local effect. For example, drugs used in the treatment of gastric disorders, such as peptic ulcers and Helicobacter pylori infections, benefit from prolonged gastric retention5.
By maintaining high drug concentrations at the site of action, GRDDS improve therapeutic efficacy and reduce systemic side effects. This targeted delivery approach is also beneficial for drugs that degrade in the intestinal environment or require an acidic medium for optimal activity4
2.5 Improved Patient Compliance:
Patient compliance is a critical factor in the success of any drug therapy. GRDDS contribute to improved compliance by reducing dosing frequency, minimizing side effects, and providing more predictable therapeutic outcomes14.
Simplified dosing regimens are particularly beneficial for elderly patients and individuals with chronic conditions, who may otherwise struggle with complex medication schedules. Additionally, the enhanced efficacy and reduced variability associated with GRDDS further support adherence to prescribed therapies.
3. Limitations of Gastroretentive Drug Delivery Systems (GRDDS):
Despite the significant advantages offered by gastroretentive drug delivery systems (GRDDS), their clinical application is associated with several limitations. These challenges arise primarily from the complex and highly variable physiological environment of the stomach, as well as formulation-related constraints. Understanding these limitations is essential for the rational design and optimization of GRDDS.
3.1 Gastric Variability:
One of the major limitations of GRDDS is the inherent variability in gastric physiology among individuals and within the same individual under different conditions. Factors such as gastric pH, motility, gastric emptying rate, and presence or absence of food can significantly influence the performance of gastroretentive systems1.
For instance, gastric emptying time can vary widely depending on the fed or fasted state, leading to unpredictable retention of the dosage form. Similarly, fluctuations in gastric pH may affect drug solubility and stability, thereby impacting drug release and absorption. This variability can result in inconsistent therapeutic outcomes and reduced reliability of GRDDS8.
3.2 Risk of Dose Dumping:
Dose dumping refers to the rapid and uncontrolled release of a drug from a dosage form, which can lead to toxicity and adverse effects. In GRDDS, this risk is particularly associated with sustained-release formulations, where failure of the delivery system due to mechanical stress, formulation instability, or environmental factors can result in sudden drug release13.
Such events can compromise patient safety, especially for drugs with a narrow therapeutic index. Therefore, careful formulation design and rigorous in vitro and in vivo evaluation are necessary to minimize the risk of dose dumping in gastroretentive systems6.
3.3 Not Suitable for Drugs Unstable in Acidic pH:
GRDDS are not suitable for drugs that are unstable or degraded in the acidic environment of the stomach. Since these systems are designed to prolong gastric residence time, drugs that undergo acid hydrolysis or exhibit poor stability at low pH may experience reduced efficacy3.
Examples include certain antibiotics and peptide-based drugs that are sensitive to gastric acid. For such compounds, alternative delivery strategies, such as enteric-coated formulations or non-oral routes, may be more appropriate3.
3.4 Dependence on Food Intake:
The performance of GRDDS is often influenced by food intake, which can significantly alter gastric physiology. The presence of food delays gastric emptying and enhances the retention of dosage forms, whereas in the fasted state, rapid gastric emptying may lead to premature expulsion of the system3.
This dependence on food can result in variability in drug release and absorption, making it challenging to achieve consistent therapeutic outcomes. Additionally, patient compliance may be affected if the dosage form must be administered under specific dietary conditions15.
4. Classification of Gastroretentive Drug Delivery Systems (GRDDS):
Gastroretentive drug delivery systems (GRDDS) are broadly classified based on their mechanism of gastric retention. These systems are designed to prolong the residence time of dosage forms in the stomach through various physiological and physicochemical approaches such as buoyancy, adhesion, expansion, density modification, or external control. Each class offers distinct advantages and is selected based on drug properties and therapeutic requirements.
Figure 2: Classification of gastroretentive drug delivery systems based on mechanisms of gastric retention, including floating, bioadhesive, swelling/expanding, high-density, magnetic, and raft-forming systems.
4.1 Floating Drug Delivery Systems (FDDS):
Floating drug delivery systems (FDDS) are among the most widely studied GRDDS. These systems are designed to have a lower density than gastric fluids, allowing them to float on the surface of the stomach contents and remain in the gastric region for an extended period16.
Effervescent Systems
Effervescent floating systems generate carbon dioxide gas upon contact with gastric fluid, which becomes entrapped within the polymer matrix, reducing the density of the dosage form and enabling flotation15. These systems typically contain gas-generating agents such as sodium bicarbonate and citric or tartaric acid.
The continuous generation of gas maintains buoyancy and ensures prolonged gastric retention. However, their performance may be influenced by gastric pH and the presence of food.
Non-Effervescent Systems
Non-effervescent systems rely on swellable polymers that form a gel-like structure upon contact with gastric fluid. Polymers such as hydroxypropyl methylcellulose (HPMC), polyethylene oxide, and carbopol are commonly used17.
These systems maintain buoyancy by increasing their volume and decreasing density without the need for gas generation. They offer more controlled drug release but may have slower onset of flotation compared to effervescent systems.
4.2 Bioadhesive/Mucoadhesive Systems:
Bioadhesive or mucoadhesive systems are designed to adhere to the gastric mucosa, thereby prolonging the residence time of the dosage form at the site of absorption18.
Mechanism of Adhesion
The adhesion process involves several mechanisms, including wetting, diffusion, adsorption, and mechanical interlocking. These interactions occur between the polymer chains and the mucus layer lining the stomach19.
Mucoadhesion enhances drug retention by resisting gastric motility and preventing premature emptying.
Polymers Used
Commonly used mucoadhesive polymers include chitosan, carbopol, polycarbophil, sodium alginate, and cellulose derivatives. These polymers exhibit strong adhesive properties and are capable of forming hydrogen bonds or electrostatic interactions with mucin20.
The choice of polymer plays a critical role in determining the strength and duration of adhesion, as well as the drug release profile.
4.3 Swelling and Expanding Systems:
Swelling and expanding systems are designed to increase in size upon contact with gastric fluid, preventing their passage through the pyloric sphincter and thereby prolonging gastric retention21.
Superporous Hydrogels
Superporous hydrogels are characterized by rapid swelling due to the presence of interconnected pores that allow quick water uptake. These systems can expand to a large size within minutes, enabling effective gastric retention22.
Expandable Matrices
Expandable matrices consist of polymers that swell gradually to form a large, rigid structure. These systems maintain their integrity in the stomach and release the drug over an extended period23.
However, they must be carefully designed to ensure safe passage through the gastrointestinal tract after drug release.
4.4 High-Density Systems:
High-density systems are designed to have a density greater than gastric fluids (>2.5 g/cm³), allowing them to sink to the bottom of the stomach and resist gastric emptying24.
Mechanism and Limitations
These systems rely on the principle of sedimentation, where the dosage form remains in the lower part of the stomach due to its high density. Materials such as barium sulfate and zinc oxide are often incorporated to increase density.
However, the effectiveness of high-density systems is limited due to the strong peristaltic movements of the stomach, which can dislodge the dosage form. Additionally, achieving the required density without compromising drug release and patient safety remains a significant challenge25.
4.5 Magnetic Systems:
Magnetic systems utilize an external magnetic field to control the position of the dosage form within the stomach. These systems contain internal magnets or magnetically responsive materials that can be retained at a specific site using an externally applied magnet26.
External Control Using Magnets
By applying a magnet over the abdominal region, the dosage form can be held in the stomach for a prolonged period, allowing targeted drug delivery.
Despite their innovative approach, magnetic systems face practical limitations such as patient compliance, precise positioning of the external magnet, and safety concerns, which have restricted their widespread clinical application.
4.6 Raft-Forming Systems:
Raft-forming systems are liquid formulations that undergo gel formation upon contact with gastric fluid. These systems typically contain alginate and bicarbonate, which react to form a viscous gel (raft) that floats on the gastric contents26.
Gel Formation in the Stomach
Upon administration, the formulation forms a cohesive gel barrier that remains in the stomach for an extended period. This raft acts as a reservoir for drug release and is particularly useful in the treatment of gastroesophageal reflux disease (GERD) and other gastric disorders27.
Raft-forming systems provide both local and systemic therapeutic effects and are widely used in clinical practice.
5. Mechanisms of Gastroretention:
The effectiveness of gastroretentive drug delivery systems (GRDDS) is primarily governed by the mechanisms through which they resist gastric emptying and remain in the stomach for prolonged periods. These mechanisms are based on physicochemical interactions with gastric contents and physiological features of the stomach. The major mechanisms include floating, adhesion, expansion, and sedimentation, each offering distinct advantages depending on the formulation strategy and drug characteristics.
5.1 Floating Mechanism:
The floating mechanism is based on the principle of buoyancy, where the dosage form remains on the surface of gastric fluids due to its lower density compared to the surrounding medium. Typically, gastric fluid has a density of approximately 1.004 g/cm³; therefore, dosage forms with lower density can float and remain in the stomach for extended durations21.
Floating systems are designed either by incorporating gas-generating agents (effervescent systems) or by using swellable polymers that reduce density (non-effervescent systems). The generation or entrapment of gas within the dosage form decreases its overall density, enabling it to float on gastric contents28.
This mechanism is particularly advantageous for drugs that are primarily absorbed in the upper gastrointestinal tract or are more soluble in acidic conditions. However, the efficiency of floating systems depends on factors such as gastric fluid volume, motility, and the presence of food29.
Figure 3: Floating mechanism showing buoyancy of dosage forms due to lower density than gastric fluid, achieved by gas generation or polymer swelling.
5.2 Adhesion Mechanism:
The adhesion mechanism involves the attachment of the dosage form to the gastric mucosal lining, thereby preventing its premature passage into the intestine. This is achieved through the use of mucoadhesive polymers that interact with mucin present in the mucus layer of the stomach29.
The adhesion process typically involves multiple steps, including wetting of the polymer, interpenetration of polymer chains with mucin, and formation of chemical bonds such as hydrogen bonding, van der Waals forces, or electrostatic interactions20.
This mechanism enhances gastric retention by anchoring the dosage form at the site of absorption, which is particularly useful for drugs requiring localized action in the stomach or prolonged exposure to the gastric environment. However, continuous mucus turnover and gastric motility may affect the duration of adhesion19.
5.3 Expansion Mechanism:
The expansion mechanism relies on the ability of the dosage form to increase in size after administration, thereby preventing its passage through the pyloric sphincter. These systems are designed using swellable or expandable polymers that absorb gastric fluid and undergo significant volumetric expansion23.
Upon swelling, the dosage form attains a size larger than the pyloric opening (approximately 12–15 mm), which allows it to remain in the stomach for prolonged periods. Superporous hydrogels and expandable matrices are commonly used in such systems due to their rapid and extensive swelling properties30.
This mechanism is highly effective in achieving prolonged gastric retention; however, it requires careful design to ensure that the expanded system can eventually reduce in size or degrade safely for passage through the gastrointestinal tract21.
5.4 Sedimentation Mechanism:
The sedimentation mechanism is based on increasing the density of the dosage form so that it sinks to the bottom of the stomach and resists gastric emptying. These high-density systems are formulated with materials such as barium sulfate or iron powder to achieve densities greater than that of gastric fluids (typically >2.5 g/cm³)24.
By settling in the lower part of the stomach, these systems avoid rapid transit through the pylorus. However, the effectiveness of sedimentation-based systems is limited due to strong gastric peristalsis, which can displace the dosage form regardless of its density31.
Additionally, achieving the required density without compromising drug release characteristics and patient safety presents a significant formulation challenge, limiting the widespread application of this mechanism.
6. Polymers Used in Gastroretentive Drug Delivery Systems (GRDDS):
Polymers play a central role in the design and performance of gastroretentive drug delivery systems (GRDDS). They are responsible for imparting key functional properties such as buoyancy, swelling, mucoadhesion, and controlled drug release. The selection of appropriate polymers is critical for achieving prolonged gastric retention and maintaining desired drug release kinetics. Broadly, polymers used in GRDDS can be classified into natural and synthetic categories, each offering distinct advantages.
6.1 Natural Polymers:
Natural polymers are widely used in GRDDS due to their biocompatibility, biodegradability, and low toxicity. These polymers are derived from plant, animal, or microbial sources and are particularly suitable for formulations requiring mucoadhesion and gel formation.
Alginate is one of the most commonly used natural polymers in gastroretentive systems. It forms a viscous gel in the presence of gastric fluid and is extensively utilized in raft-forming systems. The gel-forming ability of alginate enhances gastric retention and provides a sustained release matrix for drugs29.
Chitosan, a cationic polymer derived from chitin, exhibits excellent mucoadhesive properties due to its ability to interact with negatively charged mucin. It is widely used in bioadhesive GRDDS to prolong gastric residence time and improve drug absorption20.
Other natural polymers, such as xanthan gum, guar gum, and pectin, are also employed in GRDDS for their swelling and viscosity-enhancing properties. These polymers contribute to controlled drug release and improved stability of dosage forms21.
Despite their advantages, natural polymers may exhibit batch-to-batch variability and limited mechanical strength, which can affect formulation consistency.
6.2 Synthetic Polymers:
Synthetic polymers are extensively used in GRDDS due to their well-defined properties, reproducibility, and ability to provide precise control over drug release kinetics.
Hydroxypropyl methylcellulose (HPMC) is one of the most widely used polymers in gastroretentive formulations. It forms a gel barrier upon hydration, which controls drug release and contributes to buoyancy in floating systems. The viscosity grade of HPMC can be tailored to achieve desired release profiles32.
Carbopol (polyacrylic acid derivatives) is another important synthetic polymer known for its strong mucoadhesive properties and high swelling capacity. It is commonly used in bioadhesive and swelling systems to enhance gastric retention and sustain drug release19.
Other synthetic polymers, such as polyethylene oxide (PEO), ethyl cellulose, and Eudragit polymers, are also employed to modify drug release characteristics and improve the stability of GRDDS formulations21.
Synthetic polymers offer greater flexibility in formulation design; however, their cost and potential for reduced biocompatibility compared to natural polymers must be considered.
6.3 Role of Polymers in Drug Release:
Polymers play a crucial role in controlling drug release from GRDDS by influencing mechanisms such as diffusion, erosion, and swelling. Upon contact with gastric fluid, hydrophilic polymers absorb water and form a gel layer around the dosage form. This gel layer acts as a barrier, regulating the rate at which the drug diffuses into the surrounding medium33.
In swelling systems, polymers expand significantly, increasing the size of the dosage form and preventing gastric emptying while simultaneously controlling drug release. In mucoadhesive systems, polymers facilitate prolonged contact with the gastric mucosa, ensuring sustained drug delivery at the site of absorption23.
The physicochemical properties of polymers, including molecular weight, viscosity, and degree of cross-linking, directly affect drug release kinetics. By selecting appropriate polymer combinations, it is possible to achieve desired release profiles ranging from immediate to sustained release15.
Furthermore, polymers contribute to the mechanical stability of the dosage form, protect the drug from degradation, and enhance overall formulation performance. Advances in polymer science, including the development of smart and stimuli-responsive polymers, are expected to further improve the efficiency of GRDDS.
7. Formulation Approaches in Gastroretentive Drug Delivery Systems (GRDDS):
The design of gastroretentive drug delivery systems (GRDDS) relies on diverse formulation approaches that enable prolonged gastric residence and controlled drug release. Selection of an appropriate dosage form depends on the physicochemical properties of the drug, desired release profile, and mechanism of gastric retention. Common formulation approaches include tablets, capsules, microspheres, hydrogels, and nanoparticles, each offering unique advantages in achieving gastroretention and therapeutic efficacy.
7.1 Tablets:
Tablets are the most widely used dosage form in GRDDS due to their simplicity, cost-effectiveness, and ease of manufacturing. Gastroretentive tablets are typically designed as floating, swelling, or bioadhesive systems21.
Floating tablets incorporate gas-generating agents or swellable polymers to reduce density and enable buoyancy in gastric fluid. Swelling tablets expand upon contact with gastric fluid, preventing passage through the pylorus, while bioadhesive tablets adhere to the gastric mucosa to prolong residence time29.
These systems can provide sustained drug release and improved bioavailability. However, achieving consistent gastric retention may be challenging due to variability in gastric motility and physiological conditions.
7.2 Capsules:
Capsules are another commonly used GRDDS formulation, particularly for delivering multiparticulate systems such as pellets or beads. Gastroretentive capsules may contain floating or expandable materials that enable prolonged gastric retention28.
Capsules offer advantages such as flexibility in formulation design, ease of encapsulation of multiple units, and improved patient acceptability. They are particularly useful for delivering drugs that require controlled release through multiparticulate systems, which reduce the risk of dose dumping and provide uniform drug distribution in the gastrointestinal tract21.
7.3 Microspheres:
Microspheres are small spherical particles, typically ranging from 1 to 1000 µm in size, that can be formulated as floating or mucoadhesive systems. Floating microspheres, also known as hollow microspheres, remain buoyant in gastric fluid and provide sustained drug release23.
These systems offer several advantages, including increased surface area, uniform drug distribution, and reduced risk of localized irritation. Mucoadhesive microspheres can adhere to the gastric mucosa, further enhancing retention time and drug absorption19.
Microspheres are particularly suitable for drugs requiring controlled release and site-specific delivery in the stomach.
7.4 Hydrogels:
Hydrogels are three-dimensional polymeric networks capable of absorbing large amounts of water and swelling significantly. In GRDDS, hydrogels are used in swelling and expanding systems to increase the size of the dosage form and prevent gastric emptying22.
Superporous hydrogels, characterized by interconnected pores, enable rapid water uptake and immediate expansion, making them highly effective for gastroretention. Hydrogels also provide controlled drug release through diffusion and polymer relaxation mechanisms30.
Their biocompatibility and tunable properties make hydrogels a promising platform for advanced gastroretentive formulations.
7.5 Nanoparticles:
Nanoparticles represent an advanced formulation approach in GRDDS, offering enhanced drug delivery through improved solubility, stability, and targeting capabilities. These systems can be engineered to exhibit mucoadhesion or controlled release properties, enabling prolonged gastric retention34.
Nanoparticles can penetrate the mucus layer and provide sustained drug release at the site of action. They are particularly useful for delivering poorly soluble drugs and for achieving targeted therapy in gastric diseases15.
Despite their advantages, challenges such as scalability, stability, and regulatory considerations must be addressed for successful clinical translation.
8. Evaluation Parameters of Gastroretentive Drug Delivery Systems (GRDDS):
Evaluation of gastroretentive drug delivery systems (GRDDS) is essential to ensure their effectiveness in prolonging gastric residence time and achieving controlled drug release. Both in vitro and in vivo methods are employed to assess key parameters such as buoyancy, swelling behavior, drug release kinetics, mucoadhesive strength, and gastric retention. These evaluations provide critical insights into formulation performance and predict in vivo behavior.
8.1 In Vitro Buoyancy Studies:
In vitro buoyancy studies are conducted to assess the floating behavior of gastroretentive formulations. These studies typically involve placing the dosage form in simulated gastric fluid (pH 1.2) and measuring parameters such as floating lag time (time required for the dosage form to rise to the surface) and total floating duration (time the dosage form remains buoyant)28.
An ideal floating system should exhibit a short floating lag time and remain buoyant for an extended period. Buoyancy is influenced by factors such as polymer type, density, and gas-generating components. These studies are crucial for predicting the ability of the dosage form to remain in the gastric environment21.
8.2 Swelling Index:
The swelling index evaluates the extent to which a dosage form increases in size upon exposure to gastric fluid. It is determined by measuring the weight or volume increase of the formulation over time29.
Swelling behavior is particularly important for expanding and hydrogel-based GRDDS, as it ensures that the dosage form attains a size large enough to prevent passage through the pylorus. The swelling index is influenced by polymer composition, cross-linking density, and environmental pH23.
A higher swelling index generally correlates with improved gastric retention and controlled drug release.
8.3 Drug Release Studies:
Drug release studies are performed to evaluate the rate and extent of drug release from GRDDS. These studies are typically conducted using dissolution apparatus (USP Apparatus I or II) in simulated gastric fluid21.
The release profile helps determine whether the formulation achieves the desired sustained or controlled release. Mathematical models such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas models are often used to analyze drug release kinetics33.
Consistent and predictable drug release is essential for maintaining therapeutic efficacy and minimizing side effects.
8.4 Mucoadhesion Testing:
Mucoadhesion testing assesses the ability of the dosage form to adhere to the gastric mucosa. This is typically evaluated using in vitro or ex vivo methods involving animal gastric tissue19.
Parameters such as mucoadhesive strength, detachment force, and residence time are measured to determine the effectiveness of the adhesive interaction. Techniques such as texture analyzers and tensile strength measurements are commonly used20.
Strong mucoadhesion enhances gastric retention and ensures prolonged contact of the drug with the absorption site, thereby improving bioavailability.
8.5 In Vivo Imaging (X-ray, Gamma Scintigraphy):
In vivo imaging techniques are used to evaluate the actual gastric retention and transit behavior of GRDDS in human or animal models.
X-ray imaging involves incorporating radiopaque markers (e.g., barium sulfate) into the dosage form to visualize its position in the gastrointestinal tract31.
Gamma scintigraphy is a more advanced and sensitive technique that uses radiolabeled formulations to track the movement and residence time of the dosage form in real time24.
These imaging methods provide valuable information on gastric retention, distribution, and in vivo performance, enabling correlation with in vitro data and optimization of formulation design.
9. Applications of Gastroretentive Drug Delivery Systems (GRDDS):
Gastroretentive drug delivery systems (GRDDS) have found wide-ranging applications in the treatment of various diseases, particularly where prolonged gastric residence enhances drug absorption, stability, or local therapeutic action. These systems are especially beneficial for drugs with a narrow absorption window, drugs acting locally in the stomach, or drugs that are unstable in the intestinal environment. Key therapeutic applications are discussed below.
9.1 Antibiotics (e.g., Helicobacter pylori Treatment):
GRDDS are extensively used in the treatment of gastric infections caused by Helicobacter pylori, a bacterium associated with peptic ulcers and gastric cancer. Conventional antibiotic therapies often face challenges such as low drug concentration at the site of infection and rapid gastric emptying29.
Gastroretentive systems enable prolonged retention of antibiotics in the stomach, ensuring sustained drug release and higher local drug concentrations. This enhances eradication rates and reduces the frequency of dosing. Drugs such as amoxicillin, clarithromycin, and metronidazole have been successfully formulated into GRDDS for improved therapeutic outcomes21.
Additionally, GRDDS help in maintaining optimal drug levels in the gastric mucosa, which is critical for effective treatment of H. pylori infections.
9.2 Anti-Ulcer Drugs:
GRDDS are highly suitable for delivering anti-ulcer drugs that require prolonged action in the stomach. Drugs such as ranitidine, famotidine, and proton pump inhibitors benefit from extended gastric residence, which enhances their therapeutic efficacy28.
By maintaining sustained drug release in the stomach, GRDDS provide continuous suppression of gastric acid secretion, promoting healing of ulcers and reducing symptoms. These systems also improve drug stability in the acidic environment and reduce the need for frequent dosing21.
Raft-forming and floating systems are particularly effective for anti-ulcer therapy, as they create a protective barrier and maintain drug concentration at the site of action.
9.3 Antidiabetic Drugs:
Certain antidiabetic drugs exhibit a narrow absorption window in the upper gastrointestinal tract and therefore benefit from gastroretentive delivery. Drugs such as metformin show improved bioavailability when retained in the stomach for extended periods29.
GRDDS enable sustained release of antidiabetic agents, leading to more stable plasma glucose levels and reduced fluctuations. This improves glycemic control and minimizes side effects associated with peak drug concentrations23.
Moreover, reduced dosing frequency enhances patient compliance, which is particularly important in chronic conditions such as diabetes.
9.4 Antihypertensive Drugs
GRDDS are also applied in the delivery of antihypertensive drugs that require controlled and sustained release for effective blood pressure management. Drugs such as propranolol and verapamil, which have limited absorption windows, benefit from prolonged gastric retention25.
By maintaining consistent plasma drug levels, GRDDS help in reducing fluctuations in blood pressure and improving therapeutic outcomes. Sustained release formulations also minimize side effects and enhance patient adherence to treatment regimens24.
These systems are particularly useful in long-term management of hypertension, where maintaining steady drug levels is essential.
The translation of gastroretentive drug delivery systems (GRDDS) from research to the market demonstrates their clinical relevance and commercial viability. Several GRDDS-based products have been successfully developed and marketed, particularly for drugs requiring prolonged gastric residence, improved bioavailability, or localized action in the stomach. These formulations employ mechanisms such as floating, swelling, and raft formation to achieve therapeutic benefits.
10.1 Examples of Marketed GRDDS Products:
A number of commercially available products utilize gastroretentive principles to enhance drug delivery. Notable examples include:
A hydrodynamically balanced system (floating capsule) designed to prolong gastric retention and improve absorption of levodopa, which has a narrow absorption window in the upper gastrointestinal tract21.
A sustained-release formulation that improves gastrointestinal tolerability and maintains prolonged drug release, benefiting from extended gastric residence29.
An extended-release formulation designed to enhance bioavailability and reduce dosing frequency, particularly useful for antibiotics requiring sustained plasma levels28.
A raft-forming system that creates a viscous gel barrier in the stomach, widely used for the treatment of gastroesophageal reflux disease (GERD)27.
A controlled-release formulation that utilizes gastroretentive principles to maintain prolonged drug release and therapeutic levels21.
These marketed formulations highlight the successful application of GRDDS technologies in improving drug performance and patient outcomes.
10.2 Commercial Significance:
The commercial success of GRDDS is driven by their ability to address key limitations of conventional oral drug delivery systems. By enhancing bioavailability, reducing dosing frequency, and improving therapeutic efficacy, GRDDS provide significant value to both patients and pharmaceutical companies29.
From an industry perspective, GRDDS offer opportunities for product differentiation, lifecycle management, and patent extension. Reformulating existing drugs into gastroretentive systems can extend market exclusivity and improve clinical performance, thereby increasing commercial competitiveness24.
Additionally, the growing prevalence of chronic diseases such as diabetes, hypertension, and gastrointestinal disorders has increased the demand for advanced drug delivery systems. GRDDS align well with this demand by offering sustained and targeted drug delivery, improved patient compliance, and reduced healthcare costs associated with poor disease management23.
However, challenges such as formulation complexity, variability in gastric physiology, and regulatory considerations must be addressed to ensure consistent product performance and market acceptance.
CONCLUSION
This review comprehensively highlights the principles, classification, formulation strategies, evaluation methods, and recent advancements in gastroretentive drug delivery systems (GRDDS). The analysis demonstrates that GRDDS offer a promising approach to overcome the limitations of conventional oral drug delivery, particularly for drugs with a narrow absorption window, poor solubility in intestinal fluids, or those requiring localized action in the stomach. Various systems such as floating, mucoadhesive, swelling, and raft-forming formulations have shown significant potential in enhancing gastric retention and achieving controlled drug release.
The importance of GRDDS in modern pharmaceutics lies in their ability to improve bioavailability, reduce dosing frequency, and provide sustained therapeutic effects. By maintaining drug concentration in the stomach for extended periods, these systems enhance treatment efficacy for a wide range of conditions, including gastric infections, ulcers, diabetes, and hypertension. Advances in polymer science, nanotechnology, and formulation design have further strengthened the applicability and performance of GRDDS, making them an integral part of advanced drug delivery research.
Looking ahead, the future of GRDDS is closely linked to the integration of emerging technologies such as 3D printing, smart polymers, and artificial intelligence. These innovations are expected to enable personalized drug delivery, improved formulation precision, and better prediction of in vivo performance. However, challenges related to regulatory approval, large-scale manufacturing, and physiological variability must be addressed to ensure successful clinical translation.
In conclusion, gastroretentive drug delivery systems represent a significant advancement in oral drug delivery, offering improved therapeutic outcomes and patient compliance. Continued research and technological innovation will further expand their role in modern healthcare and pharmaceutical development.
REFERENCES
Kartik Khairnar, Tanvi Koshire, Dr. K. R. Jadhav, Yash Kokate, Mansi Jadhav, Sarthak Ghule, Rutuja Shinde, Snehal Chavan, Khushi Patodkar, Gastroretentive Drug Delivery Systems: A Comprehensive Review of Technologies, Polymers, and Therapeutic Applications, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 115-133. https://doi.org/10.5281/zenodo.19975822
10.5281/zenodo.19975822
